Paraneoplastic neuronal intermediate filament autoimmunity

Eati Basal, PhD, Nicholas Zalewski, MD, Thomas J. Kryzer, AS, Shannon R. Hinson, PhD, Yong Guo, MD, PhD, Divyanshu Dubey, MD, Eduardo E. Benarroch, MD, Claudia F. Lucchinetti, MD, Sean J. Pittock, MD, Vanda A. Lennon, MD, PhD, and Andrew McKeon, MD

Neurology® 2018;00:e1-e13. doi:10.1212/WNL.0000000000006435

Correspondence
Dr. McKeon
mckeon.andrew@mayo.edu

Abstract

Objective
To describe paraneoplastic neuronal intermediate filament (NIF) autoimmunity.

Methods
Archived patient and control serum and CSF specimens were evaluated by tissue-based indirect immunofluorescence assay (IFA). Autoantigens were identified by Western blot and mass spectrometry. NIF specificity was confirmed by dual tissue section staining and 5 recombinant NIF-specific HEK293 cell-based assays (CBAs, for α-internexin, neurofilament light [NfL], neurofilament medium, or neurofilament heavy chain, and peripherin). NIF–immunoglobulin Gs (IgGs) were correlated with neurologic syndromes and cancers.

Results
Among 65 patients, NIF-IgG-positive by IFA and CBAs, 33 were female (51%). Median symptom onset age was 62 years (range 18–88). Patients fell into 2 groups, defined by the presence of NfL-IgG (21 patients, who mostly had ≥4 NIF-IgGs detected) or its absence (44 patients, who mostly had ≤2 NIF-IgGs detected). Among NfL-IgG-positive patients, 19/21 had ≥1 subacute onset CNS disorders: cerebellar ataxia (11), encephalopathy (11), or myelopathy (2). Cancers were detected in 16 of 21 patients (77%): carcinomas of neuroendocrine lineage (10) being most common (small cell [5], Merkel cell [3], other neuroendocrine [2]). Two of 257 controls (0.8%, both with small cell carcinoma) were positive by both IFA and CBA. Five of 7 patients with immunotherapy data improved. By comparison, the 44 NfL-IgG-negative patients had findings of unclear significance: diverse nervous system disorders (p = 0.006), as well as limited (p = 0.003) and more diverse (p < 0.0001) cancer accompaniments.

Conclusions
NIF-IgG detection by IFA, with confirmatory CBA testing that yields a profile including NfL-IgG, defines a paraneoplastic CNS disorder (usually ataxia or encephalopathy) accompanying neuroendocrine lineage neoplasia.
Glossary

\(\alpha\text{IN} = \alpha\text{ internexin}; \text{ALS} = \text{amyotrophic lateral sclerosis}; \text{CBA} = \text{cell-based assay}; \text{CJD} = \text{Creutzfeldt-Jakob disease}; \text{GFAP} = \text{glial fibrillary acidic protein}; \text{IFA} = \text{immunofluorescence assay}; \text{IgG} = \text{immunoglobulin G}; \text{MS} = \text{multiple sclerosis}; \text{NfH} = \text{neurofilament heavy chain}; \text{NfL} = \text{neurofilament light chain}; \text{NfM} = \text{neurofilament medium chain}; \text{NIF} = \text{neuronal intermediate filament}; \text{PBS} = \text{phosphate-buffered saline.}

Paraneoplastic neurologic disorders are initiated as an immune response directed against one or more tumor-expressed neural autoantigens.\(^1\) Certain neural immunoglobulin G (IgG) paraneoplastic autoantibodies are disease-specific diagnostic biomarkers. Some antibodies likely have pathogenicity derived from events downstream of IgG binding to the extracellular domain of a neural protein (such as the GluN1 subunit of the NMDA receptor).\(^2\) Other antibodies, such as anti-Hu or anti-Yo, which are reactive with nuclear or cytoplasmic antigens, despite not being pathogenic, can nonetheless be specific biomarkers of cytotoxic T-cell-mediated autoimmune neurologic disorders.\(^1\) Recently, our group described a class of steroid-responsive inflammatory CNS disorders unified by glial fibrillary acidic protein (GFAP) antibody, a cytoplasmic type III intermediate astrocytic filament.\(^3,4\) The diagnosis now routinely is made in our clinical laboratory by identification of GFAP-IgG in CSF by tissue-based indirect tissue immunofluorescence assay (IFA) and confirmation by a cell-based assay (CBA) using a GFAP-transfected cell line.

Neuronal intermediate filament (NIF) antibodies have been reported previously among patients with various diseases and healthy controls, generally when tested for by a single assay type such as Western blot or ELISA.\(^5–7\) Here, we report NIF autoimmunity detected among patients referred for broad screening of neural antibodies by IFA, who had confirmation of NIF specificity by CBAs. Specificities included mature NIF forms (\(\alpha\text{ internexin} [\alpha\text{IN}], \text{neurofilament light chain} [\text{NfL}], \text{neurofilament medium chain} [\text{NfM}], \text{neurofilament heavy chain} [\text{NfH}], \text{and peripherin})), but not immature forms (vimentin or nestin) or GFAP. In particular, we focus on a group of patients who had an NIF-IgG profile that included NfL-IgG accompanied by paraneoplastic CNS autoimmunity (usually cerebellar ataxia, encephalopathy, or both) in the context of neuroendocrine neoplasia.

Control specimens tested by both IFA and CBAs (257 total: 237 sera, 20 CSF) were as follows: sera from 33 healthy controls, 63 cancer patients without neurologic symptoms (30 patients with small cell lung carcinoma, 23 patients with hepatocellular carcinoma, and 10 patients with Merkel cell carcinoma), and 20 patients with a diagnosis of a paraneoplastic neurologic disorder (anti-Hu, anti-Yo, 10 patients each), and specimens from 122 patients with diseases in whom neurofilament antibodies were previously reported in the literature including Creutzfeldt-Jakob disease (CJD; 30 sera and 10 CSF), type 1 diabetes mellitus (30 sera), CNS systemic lupus erythematosus (11 sera and 1 CSF), multiple sclerosis (MS; 20 sera and 9 CSF), and amyotrophic lateral sclerosis (ALS; 30 sera). Some historical noncancer control specimens previously tested by IFA only (354 total) were 288 healthy adult donor sera and 119 CSF from adult patients with either normal pressure hydrocephalus (66) or miscellaneous nonautoimmune neurologic disorders (53; 21 adult, 32 pediatric).

**Antigen characterization**

An algorithm demonstrating the strategy for antibody characterization and testing is outlined in figure 1. Patient and control serum and CSF specimens, and commercial monoclonal antibodies, were tested by indirect IFA on cryosections (4 \(\mu\)m) of adult mouse tissues: cerebellum, midbrain, cerebral cortex, striatum, hippocampus, kidney, and gut.\(^4\) Cutoff values of \(\leq 1:120\) for serum and \(\leq 1:2\) for CSF are long-established and clinically validated in the Mayo Clinic Neuroimmunology Laboratory. The detailed procedures for this and the following are described in data available from Dryad (appendix e-1, doi.org/10.5061/dryad.43vc36c): (1) antibody characterization (Western blotting, immunoprecipitation, mass spectrometry, antibody purification, and dual staining of tissues and cells with patient specimens and commercial IgGs); (2) NIF antibody profile testing (development of NIF-specific cell lines in-house for CBA); (3) standard clinical neural antibody testing performed; and (4) staining of tumor tissue.

**Methods**

**Standard protocol approvals, registrations, and patient consents**

The Mayo Clinic Institutional Review Board approved human specimen acquisition and review of patients’ histories (IRB 16-009814).

**Study population**

The Mayo Clinic Neuroimmunology Laboratory tested by tissue IFA, on a service basis, 616,025 serum and CSF specimens submitted for patients undergoing workup for a suspected paraneoplastic neurologic or autoimmune encephalitic illness. Either of 2 distinctive neuronal filamentous patterns of IgG reactivity was observed by IFA in serum, CSF, or both in 85 patients.
and permeabilized (0.2% Triton-X-100, 10 minutes). Normal goat serum (10%) was applied for 30 minutes to block nonspecific IgG binding. Patient or control serum (1:600 dilution) and CSF (1:5) were added to the cells for 90 minutes at room temperature. The CBA dilution of 1:600 was the optimized dilution whereby all our patient sera (NIF-IgG-positive by IFA) remained robustly positive (having also been tested with the same results at 1:100, 1:200, and 1:400), with the least amount of nonspecific staining among controls. All of our patient sera and CSF that were IFA-positive remained unambiguously positive at 1:600 and 1:5, respectively, by CBAs.

Cells were washed in phosphate-buffered saline (PBS) and secondary antibody (TRITC-conjugated goat antihuman IgG, 1:200) was applied for 45 minutes. After washing cells in PBS, slides were mounted in Prolong Gold anti-fade reagent containing 4,6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR).

Statistical methods
Neurologic disorder type and cancer frequency and histologic type for NIF-IgG patient groups were compared by Fisher exact test (JMP).

Data availability
Data available from Dryad, doi.org/10.5061/dryad.43vc3c6.

Results
Between January 1, 1993, and April 30, 2017, the Mayo Clinic Neuroimmunology Laboratory identified 2 distinctive neuronal filamentous-appearing patterns of IgG reactivity by IFA in serum or CSF of 85 patients (with 90 available specimens: containing 4,6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR).
serum, 65; CSF, 25) among 616,025 serum and CSF specimens tested (0.014%). Sixty-five patients with both clinical information and ≥1 specimens available were included.

**Autoantibody characterization**

**Tissue distribution of immunoreactivity**
Sera (48) and CSF specimens (19) from all 65 patients intensely stained neuronal cytoplasmic filaments throughout the CNS and enteric mouse tissue composite (figure 2, A.a–C.a, E.a–G.a). Non-neural renal and gastrointestinal parenchymal tissues were nonreactive (figure 2, C.a and G.a). In the cerebellum, immunostaining of cerebellar granular layer and peri-Purkinje cell regions was intense in all 65 patients. In 42 patients, immunostaining additionally produced a blush that faded in intensity through the molecular layer, from deep (adjacent to the Purkinje cell layer) to superficial regions (pattern 1, exemplified by patient 21; figures 2A and 3A). Pattern 1 had the same appearance as staining produced by commercial IgGs reactive with αIN, NF-L, and NF-M (figures 2D and 3A and figure e-1, doi.org/10.5061/dryad.43vc3c6). For the remaining 23 patients, staining of the cerebellar molecular layer was restricted to the peri-Purkinje cell region (pattern 2, exemplified by patient 28; figures 2E and 3B). Pattern 2 had the same appearance as staining produced by commercial IgG reactive with NF-H (figures 2H and 3B and figure e-1, doi.org/10.5061/dryad.43vc3c6). The patient staining patterns did not resemble those produced by commercial IgGs reactive with nestin, vimentin, or GFAP (figure 3, D–F). Findings among serum and CSF pairs, available for 7 patients, were as follows: positive in both, 2; positive in CSF only, 5.

Median IFA antibody values were 1:3,840 in serum (range 1:240–1:245,760; normal value ≤ 1:120) and 1:8 in CSF (range 2–1,024; normal value ≤ 1:2) (table 1).

**Figure 2** Immunofluorescence patterns of patient immunoglobulin G (IgG) binding to mouse tissues.

Cerebellum (A, E), hippocampus (B, F), and gastric neuronal ganglia and nerves (C, G) exposed to serum of patient 21 (A.a–C.a) and patient 28 (E.a–G.a) or to IgGs affinity-purified from serum of those patients by acid elution from replicas of Western blotted bands (A.b–C.b [65 kDa] and E2–G2 [200 kDa]). Smooth muscle antibody in patient 21 serum partially obscures the neural staining in C.a but not C.b. For comparison, cerebellar staining by commercial α internexin IgG (D) and neurofilament heavy chain IgG (H) are demonstrated (see also figure e-1). Scale bar = 50 μm.
Immunochemical characterization using rat spinal cord

Western blot probing of rat spinal cord proteins with 5 sera (from patients 1, 2, 12, 13, and 17 [lanes 6–10, respectively], figure 4A) revealed one or more immunoreactive bands of interest per patient. Five control human IgGs were non-reactive. For patients 12 and 17, the bands with approximate kDa molecular weights of 200, 150, 70, and 65 (the same as those produced by CNS-predominant NIF-specific commercial IgGs [αIN, NfL, NfM, and NfH; figure 4A]) were...
<table>
<thead>
<tr>
<th>Study no./sex/age, y/IFA pattern</th>
<th>Serum NIF-IgG profile</th>
<th>CSF NIF-IgG profile</th>
<th>Presenting symptoms</th>
<th>Neurologic disorder</th>
<th>Cancer</th>
<th>MRI findings</th>
<th>Other test findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/M/74/1 αLMH, 30,720 NA</td>
<td></td>
<td></td>
<td>Imbalance, incoordination, diplopia</td>
<td>Cerebellar ataxia</td>
<td>None</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>2/M/80*1/1 αLMHP, 30,720 NA</td>
<td></td>
<td></td>
<td>Imbalance, incoordination</td>
<td>Cerebellar ataxia, peripheral neuropathy</td>
<td>Non-Hodgkin lymphoma</td>
<td>NA</td>
<td>Length-dependent axonal neuropathy</td>
</tr>
<tr>
<td>3/F/64/1 Neg αLMH, 4</td>
<td></td>
<td></td>
<td>Imbalance, incoordination, limb paresthesias</td>
<td>Cerebellar ataxia, peripheral neuropathy</td>
<td>Leiomyosarcoma</td>
<td>NA</td>
<td>Length-dependent axonal neuropathy; GAD65 (397 nM)</td>
</tr>
<tr>
<td>4/F/74/1 αLHP, 3,840 αLMHP, 512</td>
<td></td>
<td></td>
<td>Confusion, memory loss, imbalance, incoordination</td>
<td>Cerebellar ataxia, encephalopathy</td>
<td>Merkel cell carcinoma</td>
<td>NA</td>
<td>WBCs 11; pro 150; OCB, 5; CRMP5-IgG 1:15,360; VGKC 0.22 nM</td>
</tr>
<tr>
<td>5/F/55/1 NA αLMHP, 4</td>
<td></td>
<td></td>
<td>Diffuse pain</td>
<td>Carcinomatous meningitis</td>
<td>SCLC</td>
<td>Head/spine: meningeal enhancement</td>
<td>CSF: SCLC cells</td>
</tr>
<tr>
<td>6/F/64/1 αLM, 480 NA</td>
<td></td>
<td></td>
<td>Developed confusion, memory loss</td>
<td>Encephalopathy</td>
<td>Non-SCLC</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>7/M/52*1/1 NA αLMH, 64</td>
<td></td>
<td></td>
<td>Cognitive symptoms; anxiety and depression, suicidal</td>
<td>Encephalopathy (limbic encephalitis)</td>
<td>None</td>
<td>Bilateral limbic encephalitis</td>
<td>Normal EEG; CSF: WBCs, 6, 87% lymphs; pro 61; IgG index 0.95; IgG synth 16.62; OCB negative; VGCC-P/Q (0.18 nM), VGCC-N (0.05 nM)</td>
</tr>
<tr>
<td>8/F/74*1/1 NA αLMH, 1024</td>
<td></td>
<td></td>
<td>Nausea, vertigo, diplopia, imbalance, incoordination, dysarthria, and dysphagia</td>
<td>Cerebellar ataxia</td>
<td>Metastatic Merkel cell carcinoma to inguinal lymph node</td>
<td>Mild cerebellar volume loss</td>
<td>Pro 44, 32 cells, 72% lymphs; other indices normal</td>
</tr>
<tr>
<td>9/F/60/1 NA αLMHP, 16</td>
<td></td>
<td></td>
<td>Paresthesias in face and arms, lower extremity weakness and spasticity</td>
<td>Myelopathy</td>
<td>SCLC</td>
<td>NA</td>
<td>Elevated CSF protein</td>
</tr>
<tr>
<td>10/M/64/1 NA αLMH, 1024</td>
<td></td>
<td></td>
<td>Progressive gait and balance difficulties</td>
<td>Cerebellar ataxia</td>
<td>SCLC</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>11/F/47*1/1 αLP, 1,920 NA</td>
<td></td>
<td></td>
<td>Rapid cognitive decline, catatonia, dyskinesias</td>
<td>Encephalopathy, chorea</td>
<td>SCLC</td>
<td>Head, normal</td>
<td>EEG: dysrhythmia grade 3 bifrontal; CSF: 4 OCB, normal otherwise; NMDAR IgG positive, CSF (titer 1:4); VGKC 0.10 nM</td>
</tr>
<tr>
<td>12/M/66*1/1 αLMHP, 61,440 NA</td>
<td></td>
<td></td>
<td>Gait and balance difficulties, dysarthria, incoordination, vision loss</td>
<td>Cerebellar ataxia, retinopathy</td>
<td>Neuroendocrine carcinoma metastatic; prostate adenocarcinoma (history)</td>
<td>Head, normal</td>
<td>EMG: sensorimotor axonal neuropathy; CSF: Pro 69 mg/dL, otherwise normal; VGCC-N 0.08 nM; VGCC-P/Q 0.03 nM</td>
</tr>
<tr>
<td>13/M/63/1 NA αLMHP, 122,880</td>
<td></td>
<td></td>
<td>Subacute cognitive decline, diplopia</td>
<td>Encephalopathy, cranial neuropathies</td>
<td>Hepatocellular carcinoma</td>
<td>Enhancement of bilateral III and Vth CNs</td>
<td>NA</td>
</tr>
</tbody>
</table>

Continued
Table 1  Neurofilament light chain (NfL)–immunoglobulin G (IgG)–positive patients (continued)

<table>
<thead>
<tr>
<th>Study no./sex/age, y/IFA pattern</th>
<th>Serum NIF-IgG profile</th>
<th>CSF NIF-IgG profile</th>
<th>Presenting symptoms</th>
<th>Neurologic disorder</th>
<th>Cancer</th>
<th>MRI findings</th>
<th>Other test findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>14/F/62/1 αLMHP, 7,680</td>
<td>NA</td>
<td>αLMHP, 7,680</td>
<td>Disoriented, visual and tactile hallucinations, severe gait and coordination difficulties</td>
<td>Cerebellar ataxia, encephalopathy</td>
<td>Tibial Merkel cell carcinoma</td>
<td>Head, normal</td>
<td>CSF pro, 300 mg/dL, WBCs 97, 95% lymphs</td>
</tr>
<tr>
<td>15/F/74*/1</td>
<td>NA</td>
<td>αLMHP, 1024</td>
<td>Leg pain, vertigo, left facial weakness, spasticity of legs</td>
<td>Encephalopathy, cranial neuropathy, myelopathy</td>
<td>Small cell carcinoma of cervical lymph node (unknown primary)</td>
<td>Enhancing left facial nerve; T2 signal in the brainstem, corticospinal tracts from precentral gyrus to the medulla</td>
<td>EMG: bilateral facial neuropathies; CSF: Pro77 mg/dL, WBCs, 11, 90% lymphs; IgG synth 37.68; OCB, 9; IgG index 2.5</td>
</tr>
<tr>
<td>16/M/66/1</td>
<td>LH, 7,680</td>
<td>NA</td>
<td>Intermittent vertigo, vomiting, erectile dysfunction, early satiety, orthostatic lightheadedness</td>
<td>Episodic cerebellar ataxia, dysautonomia</td>
<td>None</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>37/M/62/1</td>
<td>αLM, 122,880</td>
<td>NA</td>
<td>Confusion, episodes of depersonalization</td>
<td>Encephalopathy</td>
<td>Hepatocellular</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>54/M/56/1</td>
<td>αLH, 3,840</td>
<td>NA</td>
<td>Numb feet and hands</td>
<td>Peripheral neuropathy</td>
<td>T-cell lymphoma</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>55/F/61*/1</td>
<td>Neg</td>
<td>αLHP, NA</td>
<td>Pain and weakness in arms, bilateral ptosis, tongue weakness</td>
<td>Encephalopathy, cranial neuropathies</td>
<td>Nil</td>
<td>Head, normal</td>
<td>EMG neurogenic changes, bulbar segment (nonprogressive)</td>
</tr>
<tr>
<td>58/M/68/1</td>
<td>Neg</td>
<td>αLMH, 4</td>
<td>Profound gait, balance, and coordination problems, cognitive decline</td>
<td>Cerebellar ataxia, encephalopathy</td>
<td>Nil</td>
<td>NA</td>
<td>CSF: Pro 88 mg/dL; WBCs, 26, 90% lymphs</td>
</tr>
<tr>
<td>59/M/87*/1</td>
<td>LMH, 480</td>
<td>αLMH, 4</td>
<td>Coarse tremor of head and extremities, gait and balance difficulties, delirium</td>
<td>Cerebellar ataxia, encephalopathy</td>
<td>Pancreatic cystic neuroendocrine</td>
<td>T2 signal abnormality and atrophy in cerebellum</td>
<td>CSF: Pro 46 mg/dL</td>
</tr>
</tbody>
</table>

Abbreviations: αLH = α internexin, light chain and heavy chain immunoglobulin Gs; αLHP = α internexin, light chain, heavy chain, and peripherin immunoglobulin Gs; αLM = α internexin, light chain and medium chain immunoglobulin Gs; αLMH = α internexin, light chain, medium chain, and heavy chain immunoglobulin Gs; αLMHP = α internexin, light chain, medium chain, heavy chain, and peripherin immunoglobulin Gs; αLP = α internexin, light chain and peripherin immunoglobulin Gs; CASPR2 = contactin-associated protein 2; CRMP-5 = collapsin-response mediator protein-5; GAD65 = glutamic acid decarboxylase, 65 kilodalton isoform; IFA = immunofluorescence assay; IgG synth = immunoglobulin G synthesis rate; LGI1 = leucine rich glioma inactivated-1; LH = light chain and heavy chain immunoglobulin Gs; LMH = light chain, medium chain, and heavy chain immunoglobulin Gs; lymphs = lymphocytes; NA = not available; Neg = negative; NIF = neuronal intermediate filaments; nM = nanomolar (nmol/L); NMDAR = NMDA receptor; OCB = oligoclonal bands; P = peripherin; PD-1 = programmed death-1; Pro = protein; SCLC = small cell lung carcinoma; VGCC-N = N-type voltage gated calcium channel; VGCC-P/Q = P/Q-type voltage gated calcium channel; WBCs = white blood cells.

* Mayo Clinic patient.

* After checkpoint inhibitor (against PD-1) therapy for cancer.

* LGI1/CASPR2-IgGs negative.
selected for an immunoprecipitation study. Analysis by in-gel digestion and mass spectrometry of proteins captured by IgGs from those 2 patients, after immobilization on magnetic beads (figure 4B), assigned the greatest number of poly-peptides to NfH (for the 200 kDa band), NfM (for the 150 kDa band), NfL (for the 70 kDa band), and αIN (for the 65 kDa band). Antigenicity inherent in the 65 and 200 kDa proteins (representative of pattern 1 and pattern 2, respectively) was further demonstrated by reapplying to tissue sections patient IgGs acid-eluted from replicate bands not subjected to Western blotting (figure 2, A.b–C.b and E.b–G.b).

Absorption experiments
Tissue IFA staining patterns produced by sera from patient 22 (pattern 1, αIN-IgG positive only) and patient 28 (pattern 2, NfH-IgG positive only) were specifically abolished by preincubating sera with recombinant human αIN and NfH, respectively (figure e-2, doi.org/10.5061/dryad.43vc3c6). However, recombinant human αIN had no effect on NfH-IgG reactivity of serum from patient 28, and NfH had no effect on αIN-IgG reactivity of serum from patient 22 (data not shown). Tissue IFA staining produced by sera from 3 patients with diverse Nf-IgG profiles (patients 1, 12, and 17) were unaffected by preincubating sera with different concentrations of the polypeptide region of coil 2B rod domain, an identical region common to all of αIN, NfL, NfM, and NfH (data not shown), consistent with the patient’s Nf-IgG profile being polyclonal rather than monoclonal.

Cell-based assay
HEK293 cells were transfected with expression plasmids encoding individual human intermediate NIFs tagged with GFP. Specificity of the NIF cell lines was confirmed by Western blotting a lysate of each using commercial Nf-specific IgGs (data not shown). Commercial Nf-specific IgGs, control and patient sera, and CSF specimens were evaluated by indirect immunofluorescence after fixation and permeabilization of cells (figure 5 and figure e-3, doi.org/10.5061/dryad.43vc3c6). IgG to another NIF (peripherin-IgG) was also tested for by the same method. This was done because our patients produced staining of myenteric and renal autonomic nerves indistinguishable from peripherin-IgG (figure e-4, doi.org/10.5061/dryad.43vc3c6) and most patients had more than 1 of the other Nf-IgGs detected.

Only 2 controls were Nf-IgG-positive by both IFA and CBA; both had small cell carcinoma
Among 257 control specimens tested by both IFA and CBAs, Nf-IgGs were detected by CBAs in 19 (7%: median number of positives, 1 [range 1–2]; table e-1, doi.org/10.5061/dryad.43vc3c6 and figure 1); always in serum. These positive findings were among 8 of 63 with cancer and no neurologic symptoms (13%; 4/23 with hepatocellular carcinoma [17%] and 4/30 with small cell carcinoma of lung [13%]), 4 of 30 with type 1 diabetes mellitus (13%), 2 of 20 with paraneoplastic neurologic disorders (10%), 2 of 33 healthy controls

Figure 4 Western blot characterization of autoantibodies

(A) Rat spinal cord proteins, reduced, denatured, and separated electrophoretically, were probed with commercial neuronal intermediate filament (Nf) immunoglobulin G (IgG) (lanes 1–4), patient IgG (patients 1, 2, 12, 13, and 17 are in lanes 6–10, respectively), or healthy control IgG (lanes 12–16). Lanes 5 and 11 are empty. Patient IgGs bind to 2 or more prominent bands (molecular weight 65 kDa, 70 kDa, 150 kDa, or 200 kDa), consistent with α internexin (αIN), neurofilament light chain (NfL), neurofilament medium chain (NfM), and neurofilament heavy chain (NfH). (B) Proteins from rat spinal cord lysate bound by patient IgGs (12 [left] and 17 [right]) and immunoprecipitated by adsorption to protein G-complexed magnetic beads were separated electrophoretically and subjected to Western blotting. Probing with 4 commercial IgGs specific for NfH, NfM, NfL, and αIN revealed bands with anticipated molecular weights for those Nf proteins. The corresponding proteins were analyzed by mass spectrometry.
Patient immunoglobulin G (IgG) binding to HEK-293 cells transfected with cDNAs encoding green-fluorescent protein (GFP)-tagged human neuronal intermediate filaments (NIFs).

Patient IgGs (red) had diverse NIF reactivities. Illustrative examples include (A) patient 2 serum bound to α internexin (αIN), neurofilament light chain (NFL), neurofilament medium chain (NFM), neurofilament heavy chain (NfH), and peripherin; (B) patient 22 serum bound solely to αIN; (C) patient 32 serum bound to NFM only; and (D) patient 28 serum bound to NfH only. Scale bar = 20 μm.
(6%), 1 of 30 with CJD (3%), 1 of 29 with MS (3%), and 1 of 30 with ALS (3%). Only 2 control sera were positive by both IFA and CBA; both had small cell carcinoma (both had pattern 1 on IFA). All CSF controls were negative by IFA and CBAs. All 354 historical control specimens screened by tissue IFA alone were negative.

**Patients were NIF-IgG-positive by both IFA and CBA**

Of 65 patients, 33 were female (51%). Median age at neurologic symptom onset was 62 years (range 18–88 years). Forty-seven sera and 21 CSF were IFA-positive and were confirmed by CBA to have 1 or more NIF-IgG specificity (table e-1, doi.org/10.5061/dryad.43vc3c6; figure 1). NIF-IgG specificities detected in serum or CSF by CBAs for the 65 patients were ≥1 of the following: aIN, 34; NfL, 21; NfM, 42; NfH, 47; peripherin, 14. Eleven patients had repeat specimens (6 sera, 5 CSF) submitted within 2 years, all of which remained positive with the same profile. Patients fell into 2 distinct clinical groups, based on the presence or absence of NfL-IgG in the profile.

**NfL-IgG-positive patients have CNS paraneoplastic autoimmunity**

There were 21 patients with a profile of NfL-IgGs that included NfL-IgG. All had pattern 1 by IFA, and 3 were positive in CSF only. The median number of NfL-IgGs positive was 4 (range 2–5). Eight were evaluated neurologically at Mayo Clinic.

Cancers contemporaneous with the onset of neurologic symptoms were detected in 16 of 21 patients (positive predictive value of 77%, table 1), 2 whose neurologic symptoms started after anti-T-cell regulatory checkpoint inhibitor therapy for cancer. Thirteen of the remaining 14 cancers were detected within 3 months after serum or CSF draw for antibody testing. Cancers of neuroendocrine lineage (10; 49% of all 21 patients) were most common: small cell carcinoma (5), Merkel cell carcinoma (3, metastatic and of unknown skin primary in 2), pancreatic neuroendocrine (1), and metastatic neuroendocrine of unknown primary (1). Other neoplasms included hepatocellular carcinoma (2), non-Hodgkin lymphoma (2), uterine leiomyosarcoma (1), and non-small cell lung carcinoma (1). Duration of follow-up was short (median, 2 months; range 0–36).

Nineteen of 21 patients had subacute onset neurologic disorders affecting the CNS (table 1). The other 2 had either peripheral neuropathy (in the context of chemotherapy for T-cell lymphoma, bone marrow transplant, and graft-versus-host disease) or carcinomatous meningitis (in the context of small cell carcinoma). Neurologic diagnoses among the 19 patients were cerebellar ataxia (11; 58%), encephalopathy (11; 58%), and myelopathy (2; 11%). Four patients had encephalopathy and cerebellar ataxia coexisting (22%), 3 patients had encephalopathy and cranial neuropathies coexisting (16%), and 1 had encephalopathy and myelopathy coexisting (5%). Other coexisting disorders were peripheral neuropathy (2) and dysautonomia (1). Those with ataxia had rapidly progressive gait and coordination difficulties and appendicular cerebellar signs. Those with encephalopathy had subacute onset delirium and memory difficulties in all, and psychiatric symptoms in 4. Only 1 patient had classical limbic encephalitis. One 47-year-old woman with encephalitis had NMDA-receptor IgG coexisting, accompanied by small cell lung carcinoma, rather than ovarian teratoma. Overall, this NIF-IgG profile was 100% specific for having ≥1 of encephalopathy, cerebellar ataxia, or cancer.

At presentation, 4 of 9 patients with data available had normal head MRI scans. Abnormal findings (figure e-5, doi.org/10.5061/dryad.43vc3c6) were cerebellar atrophy in 2 ataxic patients (1 also had T2 signal abnormalities), bilateral hippocampal T2 signal abnormalities in a patient with limbic encephalitis, and cranial nerve enhancement in 2 patients with cranial neuropathies (1 with encephalomyelopathy also had diffuse brain and cord T2 signal abnormalities). Seven of 10 patients with data available had inflammatory CSF (elevated lymphocyte-predominant white cell counts or CSF-restricted oligoclonal bands) (table 1). Immunotherapy information was available for 7 patients (table e-2, doi.org/10.5061/dryad.43vc3c6), 5 of whom improved. Four patients had progressive neurologic symptoms and died, one of whom had received immunotherapy.

**NfL-IgG-negative patients had findings of uncertain clinical significance**

The remaining 44 patients were NfL-IgG-negative (21 with pattern 1 by IFA, and 23 with pattern 2) (table e-3, doi.org/10.5061/dryad.43vc3c6). Those patients, as compared to the NfL-IgG-positive group, had diverse neurologic disorders that were less commonly CNS syndromes (27/44 vs 19/21, p = 0.006). Neurologic phenotypes included ≥1 of cognitive disorders, 18; peripheral neuropathy, 14; ataxia, 8; myelopathy, 5; anterior horn cell disorders, 2; optic neuropathies, 2; chorea, 2; and one each of demyelinating disease, myopathy, and retinopathy. These patients also less frequently had cancer (15/44 vs 16/21, p = 0.003), and were less likely to have cancers of neuroendocrine lineage (1/44 vs 10/21, p < 0.0001). The median NIF antibody-positive number was lower than in the NfL-IgG cases (2; range, 1–3), and NF-H-IgG predominated.

**Merkel cell tumor pathology**

Patient 8, with severe pan cerebellar ataxia, was seropositive for all NIF-IgGs with the exception of peripherin IgG. Her enlarged groin lymph node had immunohistochemical findings characteristic of Merkel cell carcinoma with diffuse reactivity for both cytokeratins (AE1/AE3 and CK-20) and neuroendocrine cells (synaptophysin). In addition, immunostaining was positive for aIN, NfL, NfM, and NfH, but not peripherin (figure 6).

**Discussion**

We have described a class of paraneoplastic neurologic disorder, diagnosable by screening serum or CSF for a distinctive pattern of NIF-IgG by IFA (pattern 1), and then confirming
NIF specificity by detecting a profile of at least 2, and usually ≥4 NIF-IgGs, that always includes NfL-IgG. Subacute onset and rapidly progressive CNS disorders (usually cerebellar ataxia or encephalopathy or both) were encountered in affected patients. Consistent with the diffuse nervous system distribution of NIF antigens, occasional patients had coexisting myelopathy, cranial neuropathies, retinopathy, or peripheral neuropathy. Seventy-seven percent of those 21 patients had cancer, most commonly neuroendocrine lineage neoplasms (small cell, pancreatic, or Merkel cell carcinomas). This may be an underestimate given the short duration of follow-up available and limited data available on non–Mayo Clinic patients. Supportive findings for an autoimmune diagnosis in our 21 NfL-IgG-positive patients included an inflammatory CSF in 7 of 10 with data available. Most had other clues to CNS inflammation in CSF or on MRI. Cancer specificity was supported by detection of NIF-IgG autoimmunity coexisting in a patient over 40 years of age with typical NMDAR encephalitis, but who had small cell carcinoma rather than the classically described ovarian teratoma.2 Antigen specificity was supported by the patient whose Merkel cell carcinoma had a NIF staining profile matching her NIF-IgG serologic profile. Affected patients, when treated with immunotherapy, generally improved, while those who went untreated died. Consistent with our experience, cerebellar degeneration has been reported as a paraneoplastic neurologic accompaniment of Merkel cell carcinoma.9,10 Another report demonstrated neurofilament triplet protein reactivity in sera from patients with paraneoplastic retinopathy accompanying small cell carcinoma.11,12 Our series also adds to the literature of paraneoplastic neurologic disorders arising during checkpoint inhibitor therapy for cancer.13 We also encountered 44 patients without NfL-IgG with less specific neurologic and cancer findings, which will require future study. Serologically, those patients were distinct from the NfL-IgG-positive cases: their specimens usually produced a neurofilamentous pattern of staining on IFA resembling NfH-IgG (pattern 2) and had a more limited NIF-IgG profile by CBAs (just 1–2 antibodies positive, usually including NfH-IgG).

Figure 6 Neuronal intermediate filament (NIF) expression in metastatic Merkel cell carcinoma

Metastatic tumor cells in lymph node of patient 8 (serum immunoglobulin G [IgG] positive for all NIFs except peripherin) show foci of cytokeratin immunoreactivities, AE1/AE3 (A) and CK20 (B), and universal synaptophysin immunoreactivity (C), consistent with Merkel cell carcinoma. Additional immunoreactivities demonstrated: α internexin (dln; D), neurofilament light chain (NFL; E), neurofilament medium chain (NFM; F), and neurofilament heavy chain (NfH; G); peripherin immunoreactivity was lacking (H). Scale bar = 20 μm.
While measurement of individual NIF proteins (such as phosphorylated NfH in serum and CSF of patients with ALS) has significance for neurodegenerative disease,14,15 measurements of individual NIF antibodies by ELISA, Western blot, or CBAs alone have unclear significance.5–8,16–22 Our experience of testing large numbers of controls yielded occasional positive results in serum in CBA only, among both healthy controls and patients with diverse disease states (such as MS, ALS, and CJD). In contrast, only 2 controls tested positive by both IFA and CBA. Both had small cell carcinoma without neurologic disease. Similarly, in our neurologic patients, diagnostic specificity for a paraneoplastic neurologic disorder required both positivity by screening with tissue IFA for pattern 1 and subsequent molecular confirmation by CBAs of an NIF-IgG profile that included NfL-IgG. At this early stage, evaluation of CSF in addition to serum appears to improve testing sensitivity.

αIN, Nfl, NfM, and NfH are Class IV neuronal intermediate filaments widely expressed in mature central, peripheral, and autonomic neurons.23 Peripherin is a type III NIF expressed predominantly in the peripheral nervous system.24 NIFS support structure and functions such as transport and conduction of neuronal dendrites and axons throughout the nervous system.25–27 Nfl, NfM, and NfH, so called because of their molecular weights, are obligate heteropolymers, known as neurofilament triplet proteins. As experienced with GFAP IgG, overexpression of a single GFP-tagged NIF in HEK-293 cells, without other NIF binding partners present, results in GFP-positive NIF inclusion bodies, rather than well-formed neurofilamentous tertiary structures. This did not hinder CBA interpretation.3,4 As is usually the case for paraneoplastic neurologic disorders, it is likely that NIF autoimmunity is cytotoxic T cell–mediated, and not antibody-mediated, given the exclusively cytoplasmic localization of NIF proteins.1

In normal skin, nerve fibers immunoreactive for NIFs are restricted to free nerve endings in the epidermis, dermal papilla, and Meissner corpuscles.28,29 In contrast, neurofilament triplet proteins and αIN expression were diffusely expressed in metastatic cutaneous neuroendocrine (Merkel cell) neoplasm from patient 8 with cerebellar ataxia. The tumor’s NIF immunoreactivity matched the patient’s serum NIF-IgG profile (positive for 4 of 5, excluding peripherin). Consistent with the diversity of oncologic accompaniments encountered in our patients, NIF proteins are known to be expressed in lung carcinomas (both small cell and non-small-cell), neuroendocrine neoplasms, breast adenocarcinoma, sarcomas, and neuroblastomas.30–35 Though triton-insoluble, obtaining a NIF-enriched substrate for our Western blot was assured by solubilizing rat spinal cord in 8M urea.24

Neuronal precursor cells express the intermediate filaments nestin (type VI) and vimentin (type III) but their expression declines when these cells exit the cell cycle and differentiate into neurons.36 Tissue staining with commercial nestin and vimentin antibodies did not colocalize with our patient NIF-IgGs. All intermediate filaments are composed of a central α-helical rod domain flanked by N- (head) and C- (tail) terminals.37 In the rod domain, polypeptide dimers associate in parallel (known as coiled-coils). Differential amino acid sequences of nonconserved coiled-coil and C-terminal regions allow for diversity of structure and function of intermediate filaments.37,38 Consistent with a polyclonal response against NIF tertiary intermediate filament structures, our patients had diverse NIF-IgG profiles, and did not have a monoclonal reactivity with a highly conserved region common to all NIFS.

Patients with subacute onset of encephalopathy, ataxia, or myelopathy can undergo screening of serum and CSF by immunohistochemical techniques for both common and rare causes of paraneoplastic neurologic autoimmunity, including the pattern 1 of neurofilamentous staining we describe. Where CBAs confirm a profile of NIF-IgGs that includes positivity for NfL-IgG, a search for cancer (in particular those of neuroendocrine lineage) should be undertaken, and a trial of immunotherapy considered.

Author contributions

Acknowledgment
The authors acknowledge the Mayo Clinic Center for Individualized Medicine and the Department of Laboratory Medicine and Pathology for provision of funding for this research; Vickie Mewhorter and Nancy Peters for technical support; Avi Gadoth, MD, for critical review of the figures; Masoud Majed, MD, for statistical support; and P. Pearse Morris, MD, for assistance with radiologic data interpretation.

Study funding
No targeted funding reported.

Disclosure
E. Basal and N. Zalewski report no disclosures relevant to the manuscript. T. Kryzer is named inventor on a patent relating to AQP4 and MAP1B antibodies as markers of autoimmune neurologic disease. S. Hinson, Y. Guo, D. Dubey, and E. Benarroch report no disclosures relevant to the manuscript. C. Lucchinetti has received funding support from Biogen, Novartis, and Mallinkrodt and shares in royalties from marketing kits for detecting AQP4 autoantibody. S. Pittock holds patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker; has patents pending for MAP1B-IgG and Septin-5-IgG as markers of neurologic autoimmunity and paraneoplastic disorders; consulted for Alexion and MedImmune; and received research support
from Grifols, Medimmune, and Alexion. All compensation for consulting activities is paid directly to Mayo Clinic. V. Lennon is named inventor on a patent relating to AQP4 as NMO antigen, and a pending patent related to AQP4 and cancer. Earnings to date from licensing this technology have exceeded the federal threshold for significant interest. A. McKeon has patents pending for MAP1B-IgG and Septin-5-IgG as markers of neurologic autoimmunity and paraneoplastic disorders; consulted for Grifols, Medimmune, and Euroimmun; and received research support from Medimmune and Euroimmun but has not received personal compensation. Go to Neurology.org/N for full disclosures.

Received April 3, 2018. Accepted in final form July 23, 2018.

References

Neurology.org/N